Digital Health Promotion Program for Older Adults with Cancer
Cancer, Older adults, Balance and Resistance Activities
Neoplasm Metastasis+1
+ Neoplasms
+ Neoplastic Processes
Supportive Care Study
Summary
Study start date: May 30, 2025
Actual date on which the first participant was enrolled.This study explores whether a digital health program called COBRA is a safe and practical option for older adults who have cancer. The focus is on using balance and resistance activities to help these individuals. The study aims to assess if such a program can be effectively used by this age group, providing an important step in improving supportive care and quality of life for older cancer patients. Participants in the study will engage in an 8-week digital health program specifically designed for them. The program will likely include activities that promote balance and resistance, which are crucial for maintaining strength and stability. Researchers will monitor the participants to evaluate the feasibility and safety of the program, ensuring it is a suitable option for older adults with cancer. While specific risks and benefits are not detailed, the study is crucial for understanding how to better support the health and well-being of this population.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.38 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Supportive Care Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Older Adult Patients with Cancer - Are within 1 year of completion of primary therapy for cancer OR have a diagnosis of metastatic cancer; 1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy. 2. Individuals with metastatic cancer may be included provided they have stable disease or better per most recent restaging exam at time of enrollment. i. Patients with stable metastatic bony disease at most recent restaging exam and a score of 0-2 on the Functional Pain Scale (FPS69; Appendix 18) are eligible. The PI will consult with the Rehab Med co-PI for FPS scores of 3 or greater, by patient request or PI discretion. ii. Patients with symptomatic visceral metastases will be evaluated on a case-by-case basis at time of enrollment. * Are aged 65 years and older, with no upper age limit; * ECOG PS 0-3 or Karnofsky PS greater than or equal to 40; * Can read and speak English; * Self-report access to internet connection sufficient to support videoconferencing. Clinicians * Licensed clinician (MD, RN, APP) with an interest in the care of older adults with cancer. Exclusion Criteria: Older Adult Patients with Cancer * Have any cognitive impairment, neurologic, musculoskeletal, or other comorbid condition (as assessed by their provider) that would prevent the individual from engaging with the digital health coaching program or complete study assessments or engage in progressive intensity levels of physical activity * Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to safely engage in progressive intensity levels of physical activity (as assessed by their provider). Patients with metastatic disease and suspected interim progression since last restaging exam will be referred back to their primary oncology care team for evaluation prior to enrollment. * Have activity restrictions post-surgery at the time of enrollment Clinicians No expected exclusions
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 6 locations
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, United StatesMemorial Sloan Kettering Suffolk-Commack (Consent Only)
Commack, United StatesMemorial Sloan Kettering Westchester (Consent only)
Harrison, United States